|
|
Volumn 83, Issue 12, 2000, Pages 1599-1606
|
|
Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours
a
|
|
Author keywords
CT 2584 HMS; Pharmacokinetic; Phase I; Phosphatidic acid
|
|
Indexed keywords
1 (11 DODECYLAMINO 10 HYDROXYUNDECYL) 3,7 DIMETHYLXANTHINE HYDROGEN METHANESULFONATE;
ANTINEOPLASTIC AGENT;
CT 2584 HMS;
PHOSPHATIDIC ACID;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CYTOTOXICITY;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG FORMULATION;
DRUG HALF LIFE;
FEMALE;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
LETHARGY;
MALAISE;
MALE;
MAXIMUM TOLERATED DOSE;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SOLID TUMOR;
TREATMENT OUTCOME;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS;
AREA UNDER CURVE;
ARRHYTHMIA;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FATIGUE;
FEMALE;
HEMATURIA;
HUMANS;
HYPERSENSITIVITY;
HYPOTENSION;
INFUSIONS, INTRAVENOUS;
MALE;
MIDDLE AGED;
MYOCARDIAL ISCHEMIA;
NAUSEA;
NEOPLASMS;
PHOSPHATIDIC ACIDS;
PROTEINURIA;
TREATMENT OUTCOME;
VOMITING;
XANTHINES;
|
|
EID: 0034544643
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: 10.1054/bjoc.2000.1503 Document Type: Article |
|
Times cited : (2)
|
|
References (12)
|
